Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.

Camillo Porta, Ilaria Imarisio, Mara De Amici, Lucia Bonomi, Chiara Paglino, Elisa Biscaldi, Matteo Zimatore, Andrea Sartore-Bianchi, Marco Danova, Remigio Moratti, Alberto Riccardi

Research output: Contribution to journalArticlepeer-review


Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05%), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44%) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalOncology Reports
Issue number4
Publication statusPublished - Apr 2005

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.'. Together they form a unique fingerprint.

Cite this